SCHEMBL2560197

SCHEMBL2560197

COc1cc(Cl)c(C)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
CYP3A4 P08684 3/20 0.50
CYP1A1 P04798 4/20 0.40
CYP1B1 Q16678 4/20 0.40
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 3/20 0.38
GAA P10253 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
MAPT P10636 1/20 0.38
ACHE P22303 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9847949 0.87 ALDH1A1 (0.46) ALDH1A1CYP3A4CYP1A1CYP1B1CA1
SCHEMBL19709408 0.85 ALDH1A1 (0.43) ALDH1A1CYP3A4CYP1A1CYP1B1CA1
SCHEMBL13696428 0.85 ALDH1A1 (0.45) ALDH1A1CYP3A4CYP1A1CYP1B1CA1
SCHEMBL15334771 0.84 TAAR1 (0.44) ALDH1A1CYP3A4CYP1A1CYP1B1KDM4E
SCHEMBL25991978 0.80 CYP3A4 (0.43) ALDH1A1CYP3A4CYP1A1CYP1B1CA1
SCHEMBL25991980 0.80 GAA (0.39) ALDH1A1CYP3A4CA1CA2CA12
SCHEMBL1047515 0.80 ALDH1A1 (0.56) ALDH1A1CYP3A4CYP1A1CYP1B1CA1
SCHEMBL13696815 0.79 CYP3A4 (0.42) ALDH1A1CYP3A4KDM4EHPGDGAA
SCHEMBL14331553 0.79 AR (0.41) ALDH1A1CYP3A4KDM4EGAAMEN1
SCHEMBL8430640 0.78 ALDH1A1 (0.53) ALDH1A1CYP3A4CYP1A1CYP1B1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020231917-A1 ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2020-11-19 WO disclosed
WO-2019160813-A1 ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2019-08-22 WO disclosed
US-8835423-B2 Azepine inhibitors of janus kinases INCYTE CORPORATION (US) 2014-09-16 US disclosed
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2014-06-19 US disclosed
US-20140031344-A1 AZEPINE INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2014-01-30 US disclosed
US-8563541-B2 Azepine inhibitors of Janus kinases INCYTE CORPORATION (US) 2013-10-22 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
US-7671201-B2 Phenyl substituted cyclic derivatives FMC CORPORATION (US) 2010-03-02 US disclosed
US-7504411-B2 2,3,6-Trisubstituted-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-17 US disclosed
WO-2008052075-A2 BENZOXAZINE DERIVATIVES AND USES THEREOF WYETH (US) 2008-05-02 WO disclosed
US-20080039639-A1 Chromane and chromene derivatives and uses thereof WYETH (US) 2008-02-14 US disclosed
US-20070149506-A1 Azepine inhibitors of Janus kinases INCYTE CORPORATION 2007-06-28 US disclosed
US-4471140-A OXIDATION, BASIC OXIDATION CATALYSTS, COBALT SALT AND AMINE COMPOUND THE DOW CHEMICAL COMPANY (US) 1984-09-11 US disclosed
US-4453016-A LIQUID PHASE CATALYTIC PREPARATION OF PARA-HYDROXY BENZALDEHYDE THE DOW CHEMICAL COMPANY (US) 1984-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039639-A1 Chromane and chromene derivatives and uses thereof HTR1A, CHRM1, HTR2C ALDH1A1 2329/4885CYP3A4 305/4885CYP1A1 116/4885
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R ALDH1A1 1372/4885CYP3A4 33/4885CYP1A1 73/4885
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R ALDH1A1 1372/4885CYP3A4 33/4885CYP1A1 73/4885
US-20070149506-A1 Azepine inhibitors of Janus kinases JAK1, JAK3, JAK2 ALDH1A1 3705/4885CYP3A4 3714/4885CYP1A1 3103/4885
US-20140031344-A1 AZEPINE INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 ALDH1A1 3705/4885CYP3A4 3714/4885CYP1A1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.